In Brief Segovia et al. show that TMEM176B inhibits inflammasome activation and IL1b cleavage by controlling cytosolic Ca 
INTRODUCTION
Blockade of immune checkpoints, including the cytotoxic T lymphocyte-associated protein (CTLA)-4 and the programmed cell death-1 (PD-1)/PD ligand-1 (PD-L1) pathway, have increased overall survival and progression-free survival of cancer patients.
However, only a restricted number of patients show clinical benefits (Syn et al., 2017; Binnewies et al., 2018) , suggesting that other immune inhibitory mechanisms may limit the efficacy of these treatments. In this regard, high intratumoral K + leads to T cell dysfunction by inhibiting voltage and Ca
2+
-dependent K + channels expressed in antitumoral T lymphocytes (Eil et al. ,
Significance
Therapies targeting immune checkpoint pathways have revolutionized treatment of several cancers. However, innate and adaptive mechanisms may limit the clinical efficacy of this therapeutic modality. Here, we identify the transmembrane protein 176B (TMEM176B) as an innate immune checkpoint that curtails CD8 + T cell-mediated immunity by repressing inflammasome activation. Genetic disruption or pharmacologic inhibition of TMEM176B potentiates antitumor immunity and enhances the efficacy of anti-CTLA-4 and anti-PD-1 antibodies in mice by unleashing inflammasome activation. Accordingly, an activated inflammasome signature delineates favorable clinical responses in patients receiving immune checkpoint blockers. Thus, targeting TMEM176B may influence antitumor effector mechanisms by de-repressing inflammasome activation. 2016), suggesting a role for ionic channels as regulatory checkpoints and therapeutic targets to reinforce antitumor immunity. Recognition of immunogenic tumors by innate immune sensors including the TMEM173 (STING) type I interferon pathway leads to stimulation of CD8 + T cell-mediated immunity and potentiation of CTLA-4-and PD-1-targeted therapies (Woo et al., 2014) . Within the human myeloid compartment, STING controls the NLRP3 inflammasome (Gaidt et al., 2017) , a cytosolic multiprotein complex that, once activated, cleaves caspase-1, which then processes pro-interleukin-1b (IL-1b) and pro-IL-18 to give the active and secreted forms of these pro-inflammatory cytokines (Rathinam and Fitzgerald, 2016) . Altered levels of cytosolic cations have been shown to control secretion of active IL-1b through modulation of inflammasome activation (Gong et al., 2018) . Interestingly, activation of the NLRP3 inflammasome following immunogenic chemotherapy sensitizes tumors to immune checkpoint blockers (Pfirschke et al., 2016) . However, the role of the NLRP3 inflammasome in modulating checkpoint blockade therapies has not yet been explored. Transmembrane protein 176B (TMEM176B), also known as tolerance-related and induced (TORID), has been identified as an immunoregulatory cation channel (Louvet et al., 2005; Segovia et al., 2014) . This ubiquitously expressed protein contains four transmembrane domains and an ITIM motif in its C terminus (Eon Kuek et al., 2016) . TMEM176B and its homologous TMEM176A are members of the CD20-like MS4A family of proteins (Eon Kuek et al., 2016; Louvet et al., 2005) and are highly expressed in monocytes, macrophages, and CD11b + dendritic cells (DCs) (Condamine et al., 2010) . Here we explored the role of TMEM176B in inflammasome regulation, T cell-dependent antitumor immunity and response to immune checkpoint blockade therapies.
RESULTS

TMEM176B Inhibits Activation of the NLRP3 Inflammasome
To investigate whether TMEM176B regulates inflammasome activation, we injected ATP in wild-type (WT) or Tmem176b À/À mice ( Figure 1A ). In this model, neutrophil recruitment to the peritoneal cavity relies on caspase-1/11 activation (Schroeder et al., 2017) . We observed that Tmem176b À/À mice recruited significantly more neutrophils than WT animals. To determine whether increased neutrophil recruitment upon ATP injection was dependent on inflammasome activation, we generated Tmem176b À/À Casp1 À/À double knockout (DKO) mice (Figure S1A) . Peritoneal neutrophil recruitment was almost completely inhibited in Tmem176b
Tmem176b
À/À animals ( Figure 1A ). ATP-induced neutrophil recruitment in Tmem176b À/À mice was also interrupted by injection of a caspase-1 inhibitor ( Figure S1B ). We then stimulated WT and Tmem176b À/À bone marrow-derived DCs (BMDCs)
with the well-established NLRP3 activators ATP and nigericin and determined IL-1b in culture supernatants as a readout of inflammasome activation. We observed that, for both stimuli, Tmem176b À/À BMDCs secreted significantly higher levels of IL-1b than WT DCs in a dose-and time-dependent manner (Figures 1B and 1C) . Similar findings were observed when we stimulated BMDCs with aluminum particles ( Figure S1C ). Western blot studies confirmed that the mature (cleaved) form of IL-1b was more abundant in culture supernatants from Tmem176b À/À BMDCs compared with those obtained from WT cells ( Figure 1D ). Moreover, we observed increased mature caspase-1 in supernatants from Tmem176b À/À BMDCs compared with WT cells when stimulated with ATP ( Figure 1D ). Although lower doses (2.5 mM) of nigericin induced expression of 
Casp1
À/À BMDCs treated as in (E). One experiment representative of two is shown. *p < 0.05, **p < 0.01, ****p < 0.0001; two-way ANOVA test.
(I) Determination of IL-1b in culture supernatants of THP-1-differentiated macrophages expressing GFP or GFP-TMEM176B untreated or treated for 3 h with 0.25 mg/mL LPS and then for 2 h with 2.5 mM Nig. One experiment representative of four is shown. **p < 0.01, ***p < 0.001; two-way ANOVA test.
(J) Calcium determination in WT and Tmem176b À/À BMDCs treated for 3 h with 0.25 mg/mL LPS and 0.5 mM ATP. Cells were loaded with Ca
2+
-sensitive probe Fura-2. Emission at 340/380 nm was recorded in time-lapse experiments; 0.5 mM ATP was added when indicated by the arrow. Scale bars, 10 mm. (K) Determination of IL-1b in BMDCs exposed to the NLRP3 inflammasome activator ATP as described in (E) Figure S1 .
mature caspase-1 in culture supernatants from Tmem176b
but not WT BMDCs ( Figure 1D ), higher doses (5 mM) of this NLRP3 activator induced cleavage of caspase-1 in WT DCs, whereas lipopolysaccharides (LPS) alone did not ( Figure S1D ). In agreement with this observation, flow cytometry studies using the FLICA1 reagent revealed higher caspase-1 activation in Tmem176b À/À BMDCs ( Figure 1E ), suggesting that caspase-1 may contribute to mature IL-1b secretion by Tmem176b
BMDCs. To confirm these findings, we induced inflammasome activation in WT and Tmem176b À/À BMDCs in the presence or absence of a caspase-1 inhibitor and found that IL-1b secretion was completely inhibited when caspase-1 activation was interrupted ( Figure 1F ). Moreover, IL-1b secretion was completely abrogated in Tmem176b À/À Casp1 À/À BMDCs ( Figure 1G ).
Thus, increased IL-1b secretion observed as a result of Tmem176b deficiency requires intact caspase-1 activity. Moreover, Tmem176b À/À BMDCs also secreted higher amounts of IL-18 compared with WT cells in a caspase-1-dependent manner ( Figure 1H ). We then speculated that TMEM176B overexpression may impair IL-1b secretion in cells in which the inflammasome was activated. To address this issue, THP-1-differentiated macrophages were transfected with TMEM176B/GFP or GFP alone ( Figure S1E ) and then treated with LPS and nigericin. TMEM176B overexpression impaired IL-1b secretion compared with GFPexpressing cells ( Figure 1I ); this effect was not associated with increased cell death ( Figure S1F ). Thus, cation channel TMEM176B inhibits activation of the NLRP3 inflammasome. On the other hand, TMEM176B expression in BMDCs appears to be modulated, at least in part, by inflammasome activation (Figure S1G) , suggesting bidirectional regulation of these pathways. Of note, lower TMEM176B expression was not associated with widespread inhibition of inflammatory mediators ( Figure S1G ) or with increased cell death ( Figure S1H ) in inflammasome-stimulated BMDCs.
TMEM176B Inhibits the Inflammasome through the Control of Cytosolic Ca
2+
TMEM176B is an endophagosomal non-selective monovalent cation channel (Segovia et al., 2014) . Because the NLRP3 inflammasome is tightly regulated by cytosolic K + (Muñ oz-Planillo et al., 2013) and Ca 2+ (Murakami et al., 2012 ) levels, we speculated that TMEM176B may inhibit inflammasome activation through the regulation of ion homeostasis. To address this question, we first determined cytosolic Ca 2+ levels in WT and BMDCs ( Figure 1K ). This effect was also dependent on K + efflux in WT and Tmem176b À/À BMDCs ( Figure 1L ).
We recently showed that Ca 2+ -activated K + channels are involved in ATP-triggered inflammasome activation (Schroeder et al., 2017 Figure S2C ). Accordingly, Tmem176b À/À mice inoculated with MC38 (colon), LL/2 (LLC1; lung), or EG7 (thymic lymphoma) cell lines showed higher survival ( Figure 2A ) and reduced tumor growth ( Figure S2D ) compared with WT mice. Although TMEM176B is expressed by the three tumor cell lines studied ( Figure S2E ), immune cells from tumor-bearing Tmem176b À/À animals did not show enhanced in vivo cytotoxicity against WT cells compared with tumor-bearing Tmem176b +/+ mice ( Figure S2F ), suggesting that tumor-associated TMEM176B is not immunogenic in Tmem176b À/À hosts.
To investigate the mechanisms underlying TMEM176B contribution to tumor growth, we studied inflammasome activation and found no differences in caspase-1 activation in tumors developed in WT and Tmem176b À/À mice ( Figure S2G Figure S2H ) as described (Laoui et al., 2016 To study whether increased inflammasome activation could be responsible for tumor control in mice lacking Tmem176b, we blocked IL-1b and studied EG7 tumor development. Treatment with anti-IL-1b-neutralizing antibodies, but not with control immunoglobulin G, eliminated the antitumor activity displayed by Tmem176b À/À mice ( Figure 2H ). This effect was also verified in Figure 2I ). These results suggest that diminished tumor growth observed in Tmem176b 
Casp1
À/À animals ( Figure 2L ).
Within the tumor microenvironment, CTLs from Tmem176b
À/À animals expressed lower levels of the degranulation marker CD107a than those from Tmem176b À/À mice ( Figure S5D ).
Interestingly, depletion of CTLs in Tmem176b À/À mice using an anti-CD8 antibody increased tumor growth to similar levels as those observed in WT mice ( Figure 2M ). Thus, Tmem176b deletion enhances CTL-mediated tumor control through mechanisms involving the caspase-1/IL-1b pathway. This mechanism is associated with inflammasome-dependent induction of TCRb + CD4 + RORgt + cells. Altogether, these results support a role for TMEM176B as an emerging immune checkpoint that interrupts inflammasome activation and links innate and adaptive antitumor responses.
Inflammasome Activation Reinforces Immune Checkpoint Blockade Therapies
Given the influence of Tmem176b deletion in antitumor immunity, we investigated whether targeting this ion channel might control the efficacy of immune checkpoint blockade. We found increased survival of Tmem176b À/À compared with WT tumorbearing mice following treatment with anti-CTLA-4 monoclonal antibody (mAb) ( Figure 3A ). This effect was dependent on inflammasome activation, as it was abrogated in Tmem176b Figure 3A ). To investigate this further, we in- did not reach statistical significance, there was a trend toward lower survival in those mice when treated with anti-CTLA-4 or anti-PD-1 mAb ( Figure 3C ). Moreover, we found no differences in tumor growth in mice lacking inflammasome components under control conditions ( Figures 3B and 3C ), in agreement with previous reports (Ghiringhelli et al., 2009) . These results highlight the importance of triggering inflammasome activation to improve the efficacy of checkpoint blockade therapies.
Sensitivity to Immune Checkpoint Blockers Is Associated with an ''Inflammasome-Activated'' Signature in Cancer Patients
We then investigated whether inflammasome-related genes might be associated with clinical responses in patients treated with immune checkpoint blockers. First, we analyzed wholeexome sequencing and transcriptomics data from a cohort of melanoma patients treated with immune checkpoint inhibitors (Riaz et al., 2017) . These studies focused on pre-treatment and on-treatment tumor biopsies from patients receiving anti-PD-1 mAb after progression from anti-CTLA-4 therapy (IPI-progressing) and patients treated with anti-PD-1 without previous anti-CTLA-4 treatment (IPI-naive). In non-responding patients of the IPI-naive population, only two inflammasome-related genes-TMEM176A and TMEM176B-were significantly upregulated during treatment compared with pre-treatment ( Figure 4A ; Table  S1 ). These observations emphasize the role of TMEM176 ionic channels as potential mediators of resistance to checkpoint blockade therapies. Interestingly, when comparing patients responding or not to anti-PD-1 at the pre-treatment stage, we found no significant differences in inflammasome-related genes in the entire population (Table S2) , or in the IPI-naive (Table S3) or IPI-progressed (Table S4) groups. However, eight inflammasome-related genes were significantly upregulated in responders versus non-responders in the entire population during anti-PD-1 treatment ( Figure 4B ). TMEM176A and TMEM176B were two of the inflammasome-related genes that were significantly upregulated in patients responding to anti-PD-1, suggesting that they could function as a counter-regulatory mechanism in response to treatment. Similar findings were observed in the IPI-naive population (Table S5) . We then performed a paired analysis of tumor biopsies comparing pre-treatment and on anti-PD-1 treatment from responding patients. We found 11 inflammasome-related genes that were significantly upregulated during anti-PD-1 therapy compared with pre-treatment biopsies ( Figure 4C ). Similar results were found when analyzing the IPI-naive population (Table S6) .
We then estimated the diversity of leukocyte populations infiltrating tumors using the CIBERSORT method . We observed increased relative frequencies of CD8 + T cells and activated memory CD4 + T cells during anti-PD-1 treatment versus pre-treatment in responders but not in progressors ( Figure 4D ). Absolute number of leukocytes, CD8 + T cells, and activated memory CD4 + T cells were also increased (Figure 4E) . In patients responding to anti-PD-1 therapy, the total number of leukocytes, as well as the frequency of CD8 + T cells and activated memory CD4 + T cells, were positively associated with expression of NLRP3 during ongoing treatment ( Figure 4F ). These observations reinforce the concept that inflammasome activation controls T cell immunity in patients treated with immune checkpoint blockers.
To validate further these observations, we analyzed the inflammasome gene expression profile in longitudinal tumor biopsies from melanoma patients treated sequentially with anti-CTLA-4 and anti-PD-1 mAb (Chen et al., 2016) . These authors studied gene expression profiling (GEP) via a custom 795-gene panel composed of immune and cancer-related genes which did not include TMEM176A and TMEM176B. The authors found no significant differences in GEP when comparing responders versus progressors before anti-CTLA-4 or anti-PD-1 therapy. Consistently, we found no significant expression of inflammasome-related genes at these stages ( Figures S6A, S6B , S7A, and S7B). These results are in agreement with our findings from the analysis of the Riaz et al. cohort at the pre-treatment stage (Tables S1-S4 ). However, the authors found 411 genes that were significantly regulated (mostly upregulated) in responders versus progressors following PD-1 blockade. In those patients, 15/16 inflammasome-related genes were significantly upregulated in responders compared with progressors ( Figure 5A ). We then performed a paired analysis of the 16 inflammasome-related genes in biopsies of 5 responders and 7 progressors comparing gene expression profiles before and during anti-PD-1 therapy. All these patients had progressed to anti-CTLA-4 therapy. Critically, 5/5 patients responding to anti-PD-1 mAb showed a significant upregulation of inflammasome-related genes during anti-PD-1 treatment ( Figure 5B ). Moreover, 4/7 patients who did not respond to anti-PD-1 therapy significantly downregulated the inflammasome signature during PD-1 blockade ( Figure 5B ). Thus, gene expression profiles from biopsies of two independent cohorts of melanoma patients treated with immune checkpoint blockers revealed strong association between inflammasome activation and clinical responses. These findings support the notion that inflammasome activation contributes to antitumor responses triggered by immune checkpoint blockers and highlights the value of an ''inflammasome activation'' signature as a potential biomarker of response to immune checkpoint blockade.
Pharmacologic Inhibition of TMEM176B Triggers Inflammasome-Dependent Tumor Control and Improves the Efficacy of Immune Checkpoint Blockers To identify compounds capable of improving the efficacy of immune checkpoint blockers by inhibiting TMEM176B-dependent ion flux and triggering inflammasome activation, we set up an in vitro assay. In brief, CHO-7 cells were transfected with TMEM176B-and TMEM176A-mCherry. Cells were then loaded with the Na + -sensitive fluorescent dye Asante NaTRIUM Green 2 (ANG-2). We observed increased ANG-2 mean fluorescence intensity in mCherry + compared with mCherry À cells ( Figure 6A ).
We then screened a library of compounds known to modulate ion channel activity (Data S1). We found that both enantiomers of BayK8644 potently inhibited TMEM176B-A-dependent Na + influx, while they minimally affected TMEM176B-A-negative cells ( Figures 6A, 6B , and S8A), thus prompting the study of these compounds. Whereas (+) BayK8644 is known to inhibit L-type voltage-dependent Ca 2+ channels, the (À) stereoisomer activates those channels (Hamilton et al., 1987) . Since both isomers inhibit TMEM176B/A activity, it is unlikely that our observations could be explained by their effects on Na + influx through the modulation of Ca 2+ channels. In electrophysiology studies using TMEM176B-overexpressing Xenopus oocytes, (+) BayK8644 completely inhibited TMEM176B-dependent current ( Figure 6B ). Therefore, we focused on the (+) isomer for functional experiments. We found that BayK8644 induced IL-1b secretion and caspase-1 activation in LPS-primed WT but not in Tmem176b À/À BMDCs ( Figures 6C and S8B-S8D) . Interestingly, BayK8644-induced IL-1b secretion was inhibited by the Ca 2+ -activated K + channel (KCa) inhibitors tetraethylammonium and hydroxychloroquine ( Figure 6D ). Thus, BayK8644 treatment on WT BMDCs phenocopied Tmem176b deficiency. In THP-1-differentiated macrophages, TMEM176B-dependent inhibition of IL-1b secretion was prevented when these cells were treated with BayK8644 ( Figure 6E ). These results suggest that BayK8644 triggers inflammasome activation through inhibition of TMEM176B. We then explored whether BayK8644 treatment may control tumor growth in vivo. Administration of BayK8644 significantly increased survival of tumor-bearing WT but not Tmem176b PYCARD  IL1B  IL1A  IL18  IL1R1  IL1RN  IL18RAP  IL1R2   IL18R1   IL18BP   AIM2  IL17F  NLRP6  NLRP7 (legend on next page)
BayK8644 did not induce apoptosis at similar doses as those detected in plasma after intraperitoneal injection ( Figure S8E ). To explore whether BayK8644 recapitulated the effects in tumor growth control observed in untreated Tmem176b À/À mice, we evaluated its influence on inflammasome activation by disrupting important components of this pathway. We found that BayK8644 significantly improved survival of WT but not Casp1/11 À/À tumor-bearing mice ( Figure 6G ). Consistent with this observation, BayK8644 increased the frequency of CD11b + cDCs expressing active caspase-1 in TDLN ( Figure 6H ). Moreover, BayK8644-induced tumor control was mediated by CD8 + T cells as it increased CD8 + T cell-dependent tumor cytotoxicity in vivo (Figure 6I) , and depletion of CD8 + T cells completely abolished the antitumor effect of this inhibitor ( Figures 6J and S8F) . Thus, BayK8644 restrains EG7 tumor growth in a TMEM176B-, caspase-1/11-, and CD8 + T cell-dependent manner, phenocopying Figure 6N ). This observation might be explained by concomitant CTL-mediated mechanisms required for both the antitumor activity of BayK8644 ( Figures 6J and S8F ) and anti-PD-1 mAb (Sharma and Allison, 2015) . Thus, as expected, combination treatment strongly relies on the CD8 + T cell compartment.
Furthermore, BayK8644 significantly enhanced the antitumoral effect of anti-PD-1 therapy in mice bearing 5555 melanoma (Figure 6O ), whereas this effect was apparent in LL/2 lung cancer ( Figures S8J and S8K ) and MC38 colon cancer ( Figures S8L  and S8M ) models, albeit not reaching statistical significance. Moreover, whereas BayK8644 reinforced the antitumor effects of anti-PD-1 treatment in mouse melanoma, it did not enhance tumor growth inhibition induced by anti-CTLA-4 and anti-PD-1 combination therapy, at least in this model ( Figure S8O ). Given the pharmacologic impact of channel inhibitors in cardiomyocyte function, we finally examined whether BayK8644 may lead to acute cardiac toxicity. Notably, BayK8644 treatment was not associated with electrocardiographic nor echocardiographic alterations 30 min after intravenous injection compared with mice treated with vehicle control (Tables 1 and 2 ). Thus, pharmacological inhibition of TMEM176B represents a potential therapeutic approach to unleash inflammasome activation, leading to potentiation of CD8 + T cell-dependent antitumor immunity.
DISCUSSION
In this study, we demonstrate a central role of the inflammasome in reinforcing CD8 + T cell-dependent antitumor immunity and enhancing the efficacy of checkpoint blockade therapies.
In particular, we demonstrate a key role of TMEM176B as negative regulator of inflammasome activation. Whereas most immunotherapeutic modalities have focused on drugs targeting adaptive components of the immune system, innate immune pathways may represent additional anticancer targets (Woo et al., 2014) . Although recently proposed to play a role in immunotherapy (Mangan et al., 2018) , the direct contribution of IL-1b/IL-18 inflammasomes to antitumor immunity and adaptive checkpoint blockade remains elusive (Karki et al., 2017) . Here we identify a therapeutic strategy that reinforces antitumor responses by targeting TMEM176B and promoting inflammasome disinhibition. Our results suggest that inflammasome activation plays a central role in antitumor immunity triggered by anti-CTLA-4 and anti-PD-1 mAb. Although experiments in Nlrp3 À/À animals did not reach statistical significance, studies in animals lacking the downstream effectors Casp1/11 did. These observations suggest that different inflammasomes could mediate the antitumoral effect triggered by anti-CTLA-4 and anti-PD-1 therapies. Accordingly, analysis of anti-PD-1-treated melanoma patients suggested that NLRP6, NLRP7, AIM2, and NLRC4 inflammasomes might contribute to antitumor responses unleashed by checkpoint blockers. Although the requirement of caspase-1 autoproteolysis can differ among different inflammasomes (Broz et al., 2010) , and caspase-1 may cleave other proteins than IL-1b and IL-18 (Sokolovska et al., 2013) , to our knowledge, caspase-1/11 activation mostly depends on inflammasomes. Thus, it is unlikely that observations in Casp1/11
and Tmem176b
Casp1
À/À mice could involve inflammasome-independent mechanisms. Our results suggest that TMEM176B might be a predictive marker of response to anti-PD-1 therapy. In addition, TMEM176B expression in the tumor stroma was associated with poor survival Figure 5 . Analysis of the Inflammasome Signature in Tumor Biopsies from Melanoma Patients Treated with Immune Checkpoint Blockers (A) Log2-transformed normalized NanoString counts for the indicated inflammasome-related genes in melanoma tumor biopsies from patients being treated with anti-PD-1 mAb. The results for responding and non-responding patients as defined by Chen et al. (2016) . Mean ± SD are shown. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001; unpaired Student's t test.
(B) Paired analysis of the 16 inflammasome-related genes studied in (A) comparing pre-treatment and on-treatment tumor biopsies from melanoma patients responding (n = 5) or not responding (n = 7) to anti-PD-1 therapy. *p < 0.05, ***p < 0.001, ****p < 0.0001; paired Student's t test. See also Figures S6 and S7 . in colorectal cancer patients, suggesting a potential role of this ion channel as a prognostic factor. Interestingly, TMEM176B was associated with diminished NLRP3 and IL1B expression in macrophages infiltrating human melanoma, suggesting that this ion channel may function as an innate checkpoint signal that hinders immune responses in the tumor microenvironment. However, our results in experimental models support a key role for TMEM176B in the modulation of inflammasome activation mostly in TDLN during the induction phase of antitumor responses. Thus, TMEM176B-dependent immune inhibitory mechanisms may operate within the tumor microenvironment and TDLN.
Sustained K + efflux through the voltage-gated (K v 1.3) or Ca 2+ -activated (KCa3.1) K + channels has been shown to reinvigorate tumor-infiltrating T cells (Eil et al., 2016) . The results presented here suggest that Ca 2+ -induced K + efflux in DCs may promote antitumor immunity by triggering inflammasome activation, a process that is repressed by TMEM176B.
In conclusion, our study links inflammasome activation to antitumor responses triggered by immune checkpoint blockers, highlighting a central role for TMEM176B, an ion channel expressed on myeloid cells, in repression of T cell-dependent immunity. Further efforts should be aimed at evaluating the clinical (O) Survival of WT mice inoculated with 5,555 melanoma cells and left untreated or treated either with anti-PD-1 mAb (days 6, 9, and 12), BayK8644 (days 9-21), or both. All animals had established tumors when BayK8644 treatment was started. ns, not significant. Untreated versus BayK8644 + anti-PD-1: *p < 0.05; BayK8644 versus BayK8644 + anti-PD-1: ns; anti-PD-1 versus BayK8644 + anti-PD-1: ns; untreated versus anti-PD-1: ns; untreated versus BayK8644: ns; log rank (Mantel-Cox) test. In (F), (G), and (J-O) the ratio represents the number of surviving mice/total injected mice. For these experiments we used C57BL/6 mice. Mean ± SD are shown. See also Figure S8 . efficacy and safety of inflammasome disinhibition in the treatment of cancer patients, particularly those resistant to current immunotherapies.
STAR+METHODS
Detailed methods are provided in the online version of this paper and include the following: 
CONTACT FOR REAGENT AND RESOURCE SHARING
Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Marcelo Hill (mhill@pasteur.edu.uy).
EXPERIMENTAL MODELS AND SUBJECT DETAILS Animals
Six-to-ten weeks old male or female C57BL/6 or BALB/c mice were used (Jackson Lab; Bar Harbor, ME) and bred for up to 20 generations at the Institut Pasteur Montevideo or at the Institute of Biology and Experimental Medicine (IBYME), Buenos Aires. All experiments were performed according to local regulation and approved by the Institut Pasteur de Montevideo and by the Institutional Committee for Care and Use of Laboratory Animals (CICUAL) at IBYME. Tmem176b -/-mice were generated in the 129/SvJ strain and heterozygous mice were backcrossed for 10 generations onto the C57BL/6 background (Janvier, Saint Berthevin, France) as reported (Segovia et al., 2014 
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-/-were bred at a specific pathogen-free animal facility (Institut Pasteur, Montevideo).
Cell Lines EG7 (expressing OVA antigen), LL2, CT26, THP-1 and CHO-K1 cell lines were purchased from ATCC (Manassas, VA). MC38 cells were from Kerafast (Boston, MA). The 5555 melanoma cell lines were kindly provided by R. Marais (Cancer Research UK, Manchester) and cultured as described (Hirata et al., 2015) .
Tumor Models and Treatments C57BL/6 mice were injected s.c with 1 x 10 6 MC38 colon cancer cells, 1 x 10 5 LL2 lung cancer cells, 2.5 x 10 5 5555 melanoma cells or 1 x 10 6 EG7 thymic lymphoma cells. BALB/C animals were injected with 1 x 10 5 CT26 colon cancer cells. Injection was performed alternating one WT and one Tmem176b -/-mouse until completing both groups. In treated animals, alternation was done between drug-and vehicle-treated animals. Tumor growth was measured manually every 2-3 days with a caliper. The two major diameters were taken. Mice were sacrificed when one of the diameters reached 2 cm. In experiments where anti-IL-1b, anti-IL-17A or control IgG were used, 4 mg antibody was injected i.p 7 days after inoculation of tumor cells. Injections were repeated every five days until day 27 post-injection or euthanasia. For depletion of CD8 + T cells, 100 mg YTS 169.4 antibody was injected every three days starting from the day before tumor inoculation. Depletion was confirmed in the spleen by flow cytometry. For administration of anti-CTLA-4 mAb or control IgG, 100 mg antibody was given i.p starting from day 6 after tumor inoculation. Injections were repeated every three days until day 12. Anti-PD-1 mAb or control IgG was injected (250 mg i.p) starting from day 6 and every three days until day 12. BayK8644 or vehicle control (ethanol) was given i.p at 1 mg/kg since day 3 until day 15 after tumor inoculation. In animals treated with BayK8644 and anti-CTLA-4 mAb, BayK8644 was injected at days 3-15 every day and anti-CTLA-4 at days 6, 9 and 12 after tumor inoculation. In mice treated with BayK8644 and anti-PD-1 mAb, treatment with the former started at day 9 and repeated every day until day 21 after tumor inoculation. Anti-PD-1 treatment started at day six after tumor inoculation and repeated every three days until day 12.
In Vivo Inflammasome Activation C57BL/6 animals were injected i.p with 20 mg/kg ATP. Four hr later, peritoneal lavage was performed using 5 ml PBS. Peritoneal cells were centrifuged and stained with anti-CD11b, anti-Ly6C and anti-Ly6G antibodies. Cells were analyzed by flow cytometry. The percentage of Ly6C int Ly6G hi cells within the CD11b + cell compartment (neutrophils) was determined. The absolute number of neutrophils was calculated for each condition.
In Vitro Inflammasome Activation Bone marrow-derived DCs (BMDCs) were differentiated by culturing bone marrow cells for 8 days in the presence of 0.4 ng/ml GM-CSF. At day 8, adherent cells were >95% CD11c + CD11b + MHC II int . Cells were stimulated for 3 hr with 0.25 mg/ml LPS, washed and treated with the indicated doses of ATP or nigericin. The presence of IL-1b was assessed in culture supernatants by ELISA (Biolegend, 432603) . To determine Caspase-1 activation, BMDCs were stained with FLICA1 45 min after ATP or nigericin stimulation and analyzed by flow cytometry. For Western blot, culture supernatants from BMDCs stimulated in the absence of FBS were precipitated with 20 % (v/v) TCA and washed with acetone. Cell lysates were generated with RIPA buffer in the presence of a protease inhibitor cocktail. Cell lysates and precipitates from culture supernatants were electrophoresed, blotted and probed with antiCaspase-1 (Adipogen, AG-20B-0042) or anti-IL-1b (Santa Cruz Biotechnol, sc-7884) antibodies.
THP-1 Transfection and Inflammasome Activation THP-1 monocytes were differentiated into macrophages by treatment with 0.1 mM PMA for 48 hr. Macrophages (2.5 x 10 6 ) were then detached using trypsine and nucleofected with the GFP or GFP-TMEM176B coding pcDNA1.3 plasmids using the Amaxa Cell Line Nucleofector Kit V-Lonza and nucleofector device (Amaxa). Sixteen hr later, cells were treated for 3 hr with 0.25 mg/ml LPS. Cells were washed and treated for 2 hr with 2.5 mM nigericin.
METHOD DETAILS Cytosolic Ca ++ Determination
BMDCs cultured on glass coverslips were loaded with 1 mM Fura-2 (ratiometric Ca ++ -sensitive probe) for 45 min in the dark. Cells were then washed and analyzed by time-lapse microscopy at 37 C. Fluorescence emission intensity at 510 nm was determined in individual wells alternating excitation wavelengths of 340 and 380 nm every 3 s. ATP was added when indicated at 0.5 mM.
In Vivo Cytotoxicity Assay Splenocytes from naive C57BL/6 mice were stained alternatively with 0.8 (high) or 0.08 mM (low) DDAO-SE probe. The high DDAO population was loaded for 60 min at 37 C with 50 mM SIINFEKL OVA peptide. After three washes, the high and low population were mixed at 1:1 ratio. Screening of TMEM176B Inhibitors CHO cells were transfected with pSecTag2B-PS-TMEM176A-mCherry and pSecTag2B-PS-TMEM176B-V5His plasmids using Lipofectamine 2000 for 4 hr, washed and cultured for 24 hr. Cells were then loaded with 1 mM ANG-2 for 30 min at 37 C, washed and incubated in 140 mM Na + -containing phosphate buffer or 140 mM NMDG to substitute Na + in the presence of different doses of tested drugs or vehicle controls. Cells were then analyzed by flow cytometry using a BD Accuri C6 cytometer equipped with a 488 nm laser. ANG-2 emission was detected using a band-pass filter 530/30 and mCherry was determined using a 670 LP filter. FlowJo vX.0.7 software was used for data analysis. MFI from NMDG-containing solutions was subtracted to MFI from Na + -containing solutions. A maximum of two drugs was studied in each experiment. Screened drugs were from SCREEN-WELLÒ Ion Channel ligand library (Enzo Life Sciences; Farmingdale, NY).
Immunohistochemistry of Human Colon Microarrays
Expression of TMEM176B was analyzed by immunohistochemistry on 90 specimens of human colon tumors (US Biomax, Inc; Rockville, MD). Briefly, antigenic recovery was done by boiling slides in a pressure cooker for 10 min in the presence of alkaline buffer (10 mM Tris, 1 mM EDTA, 0.05% Tween 20, pH 9.0). Anti-TMEM176B antibody (2.5 mg/ml; Abcam, ab103929) or control rabbit IgG was incubated ON at 4 C. Staining was verified using EnVision+ System-HRP-labelled polymer anti-rabbit (Dako/Agilent, Santa Clara CA). Slides were counterstained with Meyer's hematoxylin, analyzed by two independent researchers in a blind fashion and categorized as high or low/negative TMEM176B expression in the stroma and parenchyma. Expression levels were then correlated with survival information provided by US Biomax.
Electrophysiology Experiments
Oocytes were surgically removed from MS222 (0.4%)-anesthetized Xenopus laevis female and dissociated under gentle agitation by a 2-3 hr incubation in an OR2 solution (82 mM NaCl; 2 mM KCl; 1 mM MgCl 2 ; 5 mM HEPES pH 7.2) supplemented with collagenase 1A (1 mg/ml). Oocytes were then injected with 40 nl of in vitro synthesized Tmem176b mRNA at 1 mg/ml (mMessage mMachine Ultra kit). Tmem176b was fused to a signal peptide sequence (N-terminal) from pSecTag2B (Invitrogen, Carlsbad, CA) and to V5 + 6-His tags (C-terminal). The day after injection, oocytes were placed in a pH 8.0 solution (100 mM NaCl, 3 mM KCl, 2 mM MgCl 2 , 15 mM HEPES pH 8.0) changed daily. Two to three days later, currents were recorded in two-electrode voltage-clamp using a genclamp500 amplifier (Axon Inst., Foster City, CA) interfaced to a personal computer using the Digidata 1200 interface and the pClamp software (v 7.0; Axon Inst.). Prior to recording, oocytes were incubated in PMA at 0.1 mM in pH 8.0 solution for 20-30 min. Currents were filtered at 100 Hz and digitalized at 0.5 kHz before storage and further analysis. During recording, oocytes were continuously superfused with the pH 8.0 solution. The currents were quantified 5-15 min after holding the extracellular pH at 5.0. In TMEM176B-expressing oocytes, induction of an inward current was obtained by switching to a pH 5.0 solution.
Quantitative RT-PCR Total RNA from tumors and lymph nodes was isolated using TRIzol Reagent (Invitrogen, Carlsbad, CA). Reverse transcription was performed using M-MLV Reverse Transcriptase and random primers following manufacturer's instructions (Invitrogen). Gene expression was assessed with the Fast SYBR Green Master Mix reagent (Applied Biosystems, Foster City, CA). Mouse primers used in this study (Table S7) were all designed over different exons to prevent amplification of genomic DNA. Real-time PCR was performed using the ViiA 7 Real-Time PCR System (Applied Biosystems) or Eco Real-Time PCR System (Illumina). Gene expression was normalized using glyceraldehyde 3-phosphate dehydrogenase and expressed in arbitrary units using the 2ÀDDCt method.
Gene Expression Analysis
Normalized NanoString nCounter data were analyzed from Chen et al. (2016) . Gene expression data from Riaz et al (2017) were obtained from their GitHub repository (https://github.com/riazn/bms038_analysis/tree/master/data). RNA-seq count data were normalized to FPKM (fragment per kilobase per million) through the Bioconductor R package DESeq2 1.18.1. The on-treatment biopsy from patient 32 was excluded from further analyses since it presented extreme expression values.
CIBERSORT Analysis
The leukocyte signature matrix LM22 (547 genes) which discriminates 22 types of tumor-infiltrating immune cells was used for analysis. Normalized gene expression data from Riaz et al. (2017) cohort were processed with the CIBERSORT web tool (http://cibersort. stanford.edu/) setting no quantile normalization and 1.000 permutations as parameters. All samples were run with both relative and absolute modes. The first mode infers the relative cellular fraction for each cell of the LM22 matrix and the second calculates a score that reflects the absolute proportion of each cell type in the mixture.
Single Cell RNA-Seq Data Analysis Normalized single cell expression data from Jerby-Arnon et al. (2018) was obtained from Gene Expression Omnibus (Accession number GSE115978). To study gene correlations, the expression matrix was processed with the software MAGIC to deal with the undersampling of mRNA known as dropouts. R implementation of the MAGIC algorithm with default parameters (Rmagic v1.3.0) was applied. For correlation analysis, Spearman's Rank Correlation test was used.
Statistical Analyses
Statistical analyses were performed either by R project or GraphPad Prism 6 (GraphPad Software, Inc., La Jolla, CA). Survival analyses were done with the Log-rank (Mantel-Cox) test. Comparison of two experimental conditions was done with paired or unpaired Student's t test. Comparison of multiple conditions was done with one or two-way ANOVA tests. Differences in gene expression and CIBERSORT scores between responder and non-responder groups were assessed using the unpaired t-test when normality assumption was met. Otherwise, Mann-Whitney U test was used. Differences between matched pre-and on-treatment samples were evaluated with paired t-test when normality assumption was met or otherwise with Wilcoxon signed-rank test. For correlation analysis, the Pearson coefficient was used when samples passed the normality test. Spearman coefficient was used for all other cases. Shapiro-Wilk test was performed to evaluate the normality assumption for all samples.
DATA AND SOFTWARE AVAILABILITY
Mendeley dataset: https://data.mendeley.com/datasets/publish-confirmation/gvj6fc2b8v/1.
